丝氨酸/精氨酸丰富的剪接因子 2 表达与临床病理特征提示为人类肝细胞癌患者的预后因素。

Serine/arginine rich splicing factor 2 expression and clinic pathological features indicating a prognostic factor in human hepatocellular carcinoma patients.

机构信息

Department of General Surgery, Qilu Hospital Affiliated to Shandong University, Jinan, Shandong, China.

Department of Breast Surgery, Qianfoshan Hospital Affiliated to Shandong University, Jinan, Shandong, China.

出版信息

Cancer Biomark. 2018 Feb 14;21(3):681-687. doi: 10.3233/CBM-170770.

DOI:10.3233/CBM-170770

PMID:29278882

Abstract

BACKGROUND

This research was aimed to study the expression of Serine/arginine rich splicing factor 2 (SRSF2) in tissues of hepatocellular carcinoma, and explore the relationship between the expression and the clinic pathological and prognosis of human hepatocellular carcinoma (HCC).

METHODS

One hundred and fifty-three pairs HCC tissues and adjacent normal tissue were collected from January 2010 to March 2013. The expression of SRSF2 gene was detected by immunohistochemistry, western blotting and real-time quantitative polymerase chain reaction (PCR), and the relationship between the expression and the clinic pathological and prognosis of HCC being analyzed.

RESULTS

In 153 cases of hepatocellular carcinoma, SRSF2 was highly expressed in 93 cases, low expression of 60 cases, immunohistochemistry score (6.50 ± 2.82), which was significantly higher than that in adjacent normal tissues (2.94 ± 1.23) (P< 0.05). The expression of SRSF2 in HCC was not associated with gender (χ2= 0.014, P= 0.906), age (χ2= 0.007, P= 0.931), tumor size (χ2= 3.566, P= 0.059) and T stage (χ2= 2.708, P= 0.100), and was significantly correlated with tumor differentiation (χ2= 9.687, P= 0.007), lymph node metastasis (χ2= 4.827, P= 0.028), distal metastasis (χ2= 9.235, P= 0.002), tumor, node, metastasis (TNM) stage (χ2= 3.978, P= 0.046), portal vein invasion and serum alpha-fetoprotein (χ2= 14.919, P= 0.000). The expression of SRSF2 protein in hepatocellular carcinoma was positively correlated (r = 0.704, P< 0.05) with serum alpha-fetoprotein through Pearson analysis. The survival rates of SRSF2 overexpressing hepatocellular carcinoma were 74.19%, 44.09%, 26.88%, 24.73% and 21.51% at 1 year, 2 years, 3 years, 4 years and 5 years respectively, which were lower than those of SRSF2 low expression group (93.33%, 71.67%, 56.67%, 51.67% and 50.00%).

CONCLUSION

SRSF2 is highly expressed in hepatocellular carcinoma and its expression increases with the degree of tumor differentiation and TNM staging. It is related to lymph node metastasis and metastasis of tumor cells, and is positively related to serum alpha fetoprotein content, and affects the postoperative survival time of HCC patients.

摘要

背景

本研究旨在研究丝氨酸/精氨酸富含剪接因子 2（SRSF2）在肝癌组织中的表达，探讨其表达与人类肝癌（HCC）临床病理及预后的关系。

方法

收集 2010 年 1 月至 2013 年 3 月间 153 对 HCC 组织及其配对的癌旁正常组织，采用免疫组化、western blot 及实时定量 PCR 检测 SRSF2 基因的表达，分析其表达与 HCC 临床病理及预后的关系。

结果

在 153 例肝癌组织中，SRSF2 高表达 93 例，低表达 60 例，免疫组化评分（6.50±2.82）明显高于癌旁正常组织（2.94±1.23）（P<0.05）。SRSF2 在 HCC 中的表达与性别（χ2=0.014，P=0.906）、年龄（χ2=0.007，P=0.931）、肿瘤大小（χ2=3.566，P=0.059）和 T 分期（χ2=2.708，P=0.100）无关，与肿瘤分化程度（χ2=9.687，P=0.007）、淋巴结转移（χ2=4.827，P=0.028）、远处转移（χ2=9.235，P=0.002）、TNM 分期（χ2=3.978，P=0.046）、门静脉侵犯和血清甲胎蛋白（AFP）有关（χ2=14.919，P=0.000）。Pearson 分析显示，SRSF2 蛋白在肝癌中的表达与血清 AFP 呈正相关（r=0.704，P<0.05）。SRSF2 高表达 HCC 的 1 年、2 年、3 年、4 年和 5 年生存率分别为 74.19%、44.09%、26.88%、24.73%和 21.51%，低于 SRSF2 低表达组的 93.33%、71.67%、56.67%、51.67%和 50.00%。